← Open Payments lookup

NPI 1154406411: Open Payments

NPI 1154406411. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$747 in 38 payments from 9 companies in 2025. Trend: 2023 $460 · 2024 $1,705 · 2025 $747

Food & beverage: $737Education: $9
CompanyPaymentsAmount
Axsome Therapeutics, Inc.8$146
Alkermes, Inc.9$144
Neurocrine BioSciences, Inc.6$129
AbbVie Inc.4$79
Lundbeck LLC3$78
Otsuka America Pharmaceutical, Inc.4$71
Vanda Pharmaceuticals Inc.1$38
Bausch Health US, LLC2$36
Takeda Pharmaceuticals U.S.A., Inc.1$24

Products named: REXULTI, INGREZZA, Auvelity, VRAYLAR, VIVITROL, ARISTADA, FANAPT, APLENZIN.